JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A.

Journal of Pain 2003 April
Botulinum toxin A has demonstrated efficacy in relieving pain in spastic and nonspastic muscle conditions. This analgesic property has generally been attributed to muscular relaxation. This study demonstrates initial muscular relaxation and concomitant pain relief in a masticatory muscle model. However, as muscle power returns to normal, pain relief is still very evident. This result suggests that the analgesic effect attributed to botulinum toxin is more complex than simple muscular relaxation.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app